Jamie L. Studts

Jamie L. Studts

Auto-generated profile, based on publicly available information

Jamie L. Studts

University of Colorado School of Medicine

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 November 2020 in JNCI: Journal of the National Cancer Institute
Verified
Journal Article
Open access
PDF file
SFStacey A Fedewa
Stacey A Fedewa
EKElla A Kazerooni
Ella A Kazerooni
JSJamie L Studts
Jamie L Studts
RSRobert A Smith
Robert A Smith
PBPriti Bandi
Priti Bandi
GSGerard A Silvestri
Gerard A Silvestri
Background: Annual lung cancer screening (LCS) with low-dose chest computed tomography in older current and former smokers (ie, eligible adults) has been recommended since 2013. Uptake has been slow and variable across the United States. We estimated the LCS rate and growth at the national and state level between 2016 and 2018. Methods: The American College of Radiology’s Lung Cancer Screening Registry was used to capture screening events. Population-based surveys, the US Census, and cancer registry data were used to estimate the number of eligible adults and lung cancer mortality (ie, burden). Lung cancer screening rates (SRs) in eligible adults and screening rate ratios with 95% confidence intervals (CI) were used to measure changes by state and year. Results: Nationally, the SR was steady between 2016 (3.3%, 95% CI = 3.3% to 3.7%) and 2017 (3.4%, 95% CI = 3.4% to 3.9%), increasing to 5.0% (95% CI = 5.0% to 5.7%) in 2018 (2018 vs 2016 SR ratio = 1.52, 95% CI = 1.51 to 1.62). In 2018, several southern states with a high lung-cancer burden (eg, Mississippi, West Virginia, and Arkansas) had relatively low SRs (<4%) among eligible adults, whereas several northeastern states with lower lung cancer burden (eg, Massachusetts, Vermont, and New Hampshire) had the highest SRs (12.8%-15.2%). The exception was Kentucky, which had the nation’s highest lung cancer mortality rate and one of the highest SRs (13.7%). Conclusions: Fewer than 1 in 20 eligible adults received LCS nationally, and uptake varied widely across states. LCS rates were not aligned with lung cancer burden across states, except for Kentucky, which has supported comprehensive efforts to implement LCS.

16 November 2018 in The Oncologist
Verified
Journal Article
Closed access
PDF file
SPSarah N. Price
Sarah N. Price
JSJamie L. Studts
Jamie L. Studts
HHHeidi A. Hamann
Heidi A. Hamann
Background: Smoking after a cancer diagnosis negatively impacts health outcomes; smoking cessation improves symptoms, side effects, and overall prognosis. The Public Health Service and major oncology organizations have established guidelines for tobacco use treatment among cancer patients, including clinician assessment of tobacco use at each visit. Oncology care clinicians (OCCs) play important roles in this process (noted as the 5As: Asking about tobacco use, Advising users to quit, Assessing willingness to quit, Assisting in quit attempts, and Arranging follow-up contact). However, OCCs may not be using the “teachable moments” related to cancer diagnosis, treatment, and survivorship to provide cessation interventions.Materials and Methods: In this scoping literature review of articles from 2006 to 2017, we discuss (1) frequency and quality of OCCs' tobacco use assessments with cancer patients and survivors; (2) barriers to providing tobacco treatment for cancer patients; and (3) the efficacy and future of provider-level interventions to facilitate adherence to tobacco treatment guidelines.Results: OCCs are not adequately addressing smoking cessation with their patients. The reviewed studies indicate that although >75% assess tobacco use during an intake visit and >60% typically advise patients to quit, a substantially lower percentage recommend or arrange smoking cessation treatment or follow-up after a quit attempt. Less than 30% of OCCs report adequate training in cessation interventions.Conclusion: Intervention trials focused on provider- and system-level change are needed to promote integration of evidence-based tobacco treatment into the oncology setting. Attention should be given to the barriers faced by OCCs when targeting interventions for the oncologic context.Implications for Practice: This article reviews the existing literature on the gap between best and current practices for tobacco use assessment and treatment in the oncologic context. It also identifies clinician- and system-level barriers that should be addressed in order to lessen this gap and provides suggestions that could be applied across different oncology practice settings to connect patients with tobacco use treatments that may improve overall survival and quality of life.

7 June 2011 in The Journal of Behavioral Health Services & Research
Verified
Journal Article
Closed access
PDF file
HKHannah K. Knudsen
Hannah K. Knudsen
CSChristina R. Studts
Christina R. Studts
JSJamie L. Studts
Jamie L. Studts

29 March 2017 in Drug and Alcohol Dependence
Verified
Journal Article
Open access
HKHannah K. Knudsen
Hannah K. Knudsen
JHJennifer R. Havens
Jennifer R. Havens
MLMichelle R. Lofwall
Michelle R. Lofwall
JSJamie L. Studts
Jamie L. Studts
SWSharon L. Walsh
Sharon L. Walsh
Background: Buprenorphine is an effective treatment for opioid use disorder but the supply of buprenorphine physicians is currently inadequate to address the nation’s prescription opioid crisis. Perception of need due to rising opioid overdose rates is one possible reason for physicians to adopt buprenorphine. This study examined associations between rates of growth in buprenorphine physicians and prescription opioid overdose mortality rates in US states. Methods: The total buprenorphine physician supply and number of physicians approved to treat 100 patients (per 100,000 population) were measured from June 2013 to January 2016. States were divided into two groups: those with rates of prescription opioid overdose mortality in 2013 at or above the median (>5.5 deaths per 100,000 population) and those with rates below the median. State-level growth curves were estimated using mixed-effects regression to compare rates of growth between high and low overdose states. Results: The total supply and the supply of 100-patient buprenorphine physicians grew significantly (total supply from 7.7 to 9.9 per 100,000 population, p < 0.001; 100-patient supply from 2.2 to 3.4 per 100,000 population, p < 0.001). Rates of growth were significantly greater in high overdose states when compared to low overdose states (total supply b = 0.033, p < 0.01; 100-patient b = 0.022, p < 0.01). Conclusions: The magnitude of the US prescription opioid crisis, as measured by the rate of prescription opioid overdose mortality, is associated with growth in the number of buprenorphine physicians. Because this observational design cannot establish causality, further research is needed to elucidate the factors influencing physicians’ decisions to begin prescribing buprenorphine.

3 August 2009 in Bone Marrow Transplantation
Verified
Journal Article
Closed access
JSJ L Studts
J L Studts
JRJ L Ruberg
J L Ruberg
SMS A McGuffin
S A McGuffin
LRL M Roetzer
L M Roetzer